CADL - Company ID 0001841387
The table below shows Candel Therapeutics, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q2 2026 | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $201.56M | $194.83M | $86.96M | $100.69M | $92.17M | $16.56M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $204.16M |
| $197.75M |
| $90.13M |
| $103.61M |
| $93.15M |
| $18.09M |
| Property, plant & equipment | $2.00M | $2.08M | $1.36M | $1.66M | $1.97M | $2.48M |
| Goodwill | - | - | - | - | - | - |
| Total assets | $208.15M | $201.92M | $93.60M | $105.97M | $95.91M | $21.52M |
| Accounts payable | $5.15M | $3.04M | $1.12M | $1.95M | $760.00K | $296.00K |
| Total current liabilities | $12.69M | $7.05M | $10.93M | $14.71M | $20.07M | $15.27M |
| Long-term debt | - | - | - | - | - | $4.22M |
| Total liabilities | $82.02M | $63.89M | $13.47M | $15.76M | $21.23M | $36.77M |
| Retained earnings | -$278.15M | -$239.25M | -$200.89M | -$189.62M | -$184.83M | -$178.13M |
| Total equity | $126.13M | $138.03M | $80.12M | $90.21M | $74.67M | -$15.26M |